Disease-specific survival rate of patients with nodal non-Hodgkin’s lymphomas of the abdominal cavity and pelvis after chemoradiotherapy and chemotherapy

The aim of this study was to evaluate the survival of patients with nodal non-Hodgkin's lymphoma of the abdomen and pelvis. We analyzed 208 patients treated at RNRCR from 1980 to 2021. The main group (111 patients) received chemoradiotherapy (CT+RT), while the control group (97 patients) received only chemotherapy (CT) according to identical regimens, including immunotherapy with rituximab. Our data suggest the advantage of chemoradiotherapy over chemoradiotherapy in the majority of patients. The program of chemoradiotherapy in the treatment of patients with nodal infradiaphragmatic non-Hodgkin's lymphomas allowed statistically significant or at the level close to significant increase of 5- and 10-year disease-specific survival rates in the groups, regardless of the degree of malignancy of the disease and its stage. The best DSS rates of abdominal and pelvic nodal non-Hodgkin's lymphomas were observed with chemoimmunotherapy with rituximab in combination with adjuvant radiation therapy.